IL13 and asthma: As asthma often presents with obvious heterogeneous symptoms, Walsh believes that IL-4, IL-5, and IL-13 have considerable potential in the treatment of asthma, and anti-IL-5 monoclonal antibody prevents disease exacerbation in asthmatic patients [16].